Key facts
- Dessight Biomedical’s last known valuation is $2.1M (Jun 2025).
- It has raised $13.9M; the latest was Early Stage VC in Dec 2025.
- Notable investors include GL Ventures, Fortune Capital, Linear Capital, Beijing FOF Capital, Capricornus Investments — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for Dessight Biomedical
- ·The full record, as it builds
Funding rounds
No funding rounds for Dessight Biomedical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dessight Biomedical
Operator of ophthalmic surgical systems intended for precision eye surgery and microscale medical procedures purpose. The company integrates robotics-assisted instruments, real-time operational feedback, high-precision microinjection systems, cloud-enabled data management, compliance-ready software, and advanced imaging capabilities, enabling healthcare providers and surgical centers to perform complex retinal operations with improved accuracy, reduce procedural risks, enhance patient outcomes, and streamline workflows through intelligent automation.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2021
- Employees
- 30
- Website
- dessight.cn/
- Ownership
- Privately Held (backing)
Dessight Biomedical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dessight Biomedical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dessight Biomedical in its N-PORT filings yet. We sweep new filings monthly.